After resisting calls for name change over the past several months, Isis Pharmaceuticals eventually pulled the trigger and announced that their company will now be known as Ionis Pharmaceuticals after the latest terror attacks in Paris.

Ionis Pharmaceuticals released a statement to inform the public about the name change. Because of the name change, the company will now be known on Nasdaq as IONS and will have a new official website -- www.ionispharma.com.

Chief operating officer Lynne Parshall said that they decided to rebrand because they want to be viewed as a pharmaceutical company when consumers hear their name.

"Our goal is to create medicines that will save patients' lives, and we are proud to be at the forefront of creating innovative medicines," Parshall said in a statement. "We decided to change our company name because, when people see or hear our name, we want them to think about the life-saving medicines we are developing."

Talks about the possible name change intensified in September, when founder Stanley Crooke appeared on Mad Money, which is hosted by investor Jim Cramer. During the interview, Cramer said that the company is having problems because their name is similar to the ISIS terror group that is creating havoc in several countries.

Crooke, as quoted by Forbes, said that he does not "want to capitulate" to the terrorist, which is why he is against the idea of name change. He pointed out back then that the group is known in most countries as ISIL, not ISIS. But after the terror attacks in Paris, which killed 130 people and left hundreds wounded, Crooke said that he had to make the difficult decision.

"My underlying concern was that the name was a distraction," Crooke told Forbes. "To spend any time during a four-minute TV interview, for example, discussing our name, rather than focusing on how exciting things are at Isis today with three drugs finishing Phase 3 development and a pipeline of 40 drugs, just makes no sense."

Crooke added that they decided to rebrand to Ionis Pharmaceuticals not just because their previous name is becoming a huge distraction to investors and consumers but also to protect their employees. He pointed out that their employees could face security issues in other countries and could be attacked at home because of their connection to "Isis."

Crooke said that the company will use the same marketing strategy they implemented before. He is also hoping that their investors will now focus on the future of Ionis Pharmaceuticals now that the problematic "Isis" name is now a thing of the past.